C2 and C2C12 murine skeletal myoblast models of atrophic and hypertrophic potential: Relevance to disease and ageing?

Journal of Cellular Physiology

Volumn 225, Issue 1, 2010, Pages 240-250

  Sharples, Adam P ^a   Al Shanti, Nasser ^a   Stewart, Claire E ^a  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; MESSENGER RNA; MYOD PROTEIN; MYOGENIN; PROTEIN; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRYPAN BLUE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; MYOD1 MYOGENIC DIFFERENTIATION PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; TNFRSF1A PROTEIN, MOUSE;

AGING; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CLONING; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVITY; MOUSE; MUSCLE ATROPHY; MUSCLE HYPERTROPHY; MYOBLAST; MYOTUBE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; ATROPHY; CELL LINE; CYTOLOGY; DRUG EFFECT; GENETICS; HYPERTROPHY; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

MURINAE;

AGING; ANIMALS; ATROPHY; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CREATINE KINASE; HYPERTROPHY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR I; MICE; MOLECULAR SEQUENCE DATA; MUSCLE, SKELETAL; MYOBLASTS; MYOD PROTEIN; MYOGENIN; RECEPTOR, IGF TYPE 1; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956523695     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22252     Document Type: Article

References (56)

1. Al-Shanti N, Stewart CE. 2008. PD98059 enhances C2 myoblast differentiation through p38 MAPK activation: A novel role for PD98059. J Endocrinol 198:243-252.
2. Al-Shanti N, Saini A, Faulkner SH, Stewart CE. 2008. Beneficial synergistic interactions of TNF-alpha and IL-6 in C2 skeletal myoblasts - Potential cross-talk with IGF system. Growth Factors (Chur, Switzerland) 26:61-73.
3. Arber S, Halder G, Caroni P. 1994. Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation. Cell 79:221-231. (Pubitemid 24324913)
4. Argiles JM, Busquets S, Toledo M, Lopez-Soriano FJ. 2009. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 3:263-268.
5. Berkes CA, Tapscott SJ. 2005. MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol 16:585-595.
6. Binkert C, Landwehr J, Mary JL, Schwander J, Heinrich G. 1989. Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2). EMBO J 8:2497-2502. (Pubitemid 19273331)
7. Blau HM, Pavlath GK, Hardeman EC, Chiu CP, Silberstein L, Webster SG, Miller SC, Webster C. 1985. Plasticity of the differentiated state. Science 230:758-766.
8. Bruunsgaard H, Andersen-Ranberg K, Hjelmborg JB, Pedersen BK, Jeune B. 2003a. Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med 115:278-283.
9. Bruunsgaard H, Ladelund S, Pedersen AN, Schroll M, Jorgensen T, Pedersen BK. 2003b. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol 132:24-31.
10. Buckingham M, Bajard L, Chang T, Daubas P, Hadchouel J, Meilhac S, Montarras D, Rocancourt D, Relaix F. 2003. The formation of skeletal muscle: From somite to limb. J Anat 202:59-68.
11. Conraads VM, Hoymans VY, Vrints CJ. 2008. Heart failure and cachexia: Insights offered from molecular biology. Front Biosci 13:325-335.
12. Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR. 1997. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signal pathways. J Biol Chem 272:6653-6662.
13. Cooper RN, Tajbakhsh S, Mouly V, Cossu G, Buckingham M, Butler-Browne GS. 1999. In vivo satellite cell activation via Myf5 and MyoD in regenerating mouse skeletal muscle. J Cell Sci 112:2895-2901.
14. Dandona P, Aljada A, Bandyopadhyay A. 2004. Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol 25:4-7. (Pubitemid 38032801)
15. Degens H, Alway SE. 2003. Skeletal muscle function and hypertrophy are diminished in old age. Muscle Nerve 27:339-347.
16. Dudgeon WD, Phillips KD, Carson JA, Brewer RB, Durstine JL, Hand GA. 2006. Counteracting muscle wasting in HIV-infected individuals. HIV Med 7:299-310.
17. Ernst CW, McCusker RH, White ME. 1992. Gene expression and secretion of insulin-like growth factor-binding proteins during myoblast differentiation. Endocrinology 130:607-615.
18. Firth SM, Baxter RC. 2002. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854.
19. Foulstone EJ, Meadows KA, Holly JM, Stewart CE. 2001. Insulin-like growth factors (IGF-I and IGF-II) inhibit C2 skeletal myoblast differentiation and enhance TNF alpha-induced apoptosis. J Cell Physiol 189:207-215.
20. Fukushima T, Kataoka H. 2007. Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma. Anticancer Res 27:3685-3692.
21. Gale CR, Martyn CN, Cooper C, Sayer AA. 2007. Grip strength, body composition, and mortality. Int J Epidemiol 36:228-235. (Pubitemid 47061603)
22. Gayraud-Morel B, Chretien F, Tajbakhsh S. 2009. Skeletal muscle as a paradigm for regenerative biology and medicine. Regen Med 4:293-319.
23. Hoeflich A, Nedbal S, Blum WF, Erhard M, Lahm H, Brem G, Kolb HJ, Wanke R, Wolf E. 2001. Growth inhibition in giant growth hormone transgenic mice by overexpression of insulinlike growth factor-binding protein-2. Endocrinology 142:1889-1898.
24. James PL, Jones SB, Busby WH, Jr., Clemmons DR, Rotwein P. 1993. A highly conserved insulin-like growth factor-binding protein (IGFBP-5) is expressed during myoblast differentiation. J Biol Chem 268:22305-22312.
25. James PL, Stewart CE, Rotwein P. 1996. Insulin-like growth factor binding protein-5 modulates muscle differentiation through an insulin-like growth factor-dependent mechanism. J Cell Biol 133:683-693.
26. 12 and NIH3T3 cells by myogenin and MEF2C. Mol Genet Genomics 281:1-10.
27. Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34.
28. Kong Y, Flick MJ, Kudla AJ, Konieczny SF. 1997. Muscle LIM protein promotes myogenesis by enhancing the activity of MyoD. Mol Cell Biol 17:4750-4760. (Pubitemid 27318150)
29. Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. 2001. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J 15:1169-1180.
30. Langen RC, Van Der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. 2004. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J 18:227-237.
31. Lees SJ, Zwetsloot KA, Booth FW. 2009. Muscle precursor cells isolated from aged rats exhibit an increased TNF-alpha response. Aging Cell 8:26-35.
32. Leger B, Derave W, De Bock K, Hespel P, Russell AP. 2008. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res 11:163B-175B.
33. Levitt RJ, Georgescu MM, Pollak M. 2005. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun 336:1056-1061.
34. Li YP, Reid MB. 2000. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 279:R1165-R1170.
35. Li YP, Lecker SH, Chen Y, Waddell ID, Goldberg AL, Reid MB. 2003. TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J 17:1048-1057.
36. Libby P. 2002. Inflammation in atherosclerosis. Nature 420:868-874.
37. McKellar GE, McCarey DW, Sattar N, McInnes IB. 2009. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev 6:410-417.
38. Meadows KA, Holly JM, Stewart CE. 2000. Tumor necrosis factor-alpha-induced apoptosis is associated with suppression of insulin-like growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts. J Cell Physiol 183:330-337.
39. Morse CI, Thom JM, Mian OS, Muirhead A, Birch KM, Narici MV. 2005. Muscle strength, volume and activation following 12-month resistance training in 70-year-old males. Eur J Appl Physiol 95:197-204. (Pubitemid 41829786)
40. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. 2005. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 54:2939-2945.
41. Rehfeldt C, Renne U, Wolf E, Höflich A. 2008. Overexpression of IGFBP-2 in transgenic mice affects muscle protein accretion, skeletal myofibre growth and metabolism. Endocr Abstr 16:376.
42. Roubenoff R. 2007. Physical activity, inflammation, and muscle loss. Nutr Rev 65:S208-S212.
43. Saini A, Al-Shanti N, Stewart CE. 2006. Waste management - Cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 17:475-486.
44. Saini A, Al-Shanti N, Faulkner SH, Stewart CE. 2008. Pro- and anti-apoptotic roles for IGF-I in TNF-alpha-induced apoptosis: A MAP kinase mediated mechanism. Growth Factors (Chur, Switzerland) 26:239-253.
45. Saini A, Faulkner S, Al-Shanti N, Stewart C. 2009. Powerful signals for weak muscles. Ageing Res Rev 8:251-267.
46. Sayer, AA, Syddall HE, Martin HJ, Dennis EM, Roberts HC, Cooper C. 2006. Is grip strength associated with health-related quality of life? Age Ageing 35:409-415.
47. Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108. (Pubitemid 351818697)
48. Shi X, Garry DJ. 2006. Muscle stem cells in development, regeneration, and disease. Genes Dev 20:1692-1708.
49. So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, Pollak M. 2008. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 14:6944-6954.
50. Stewart CE, Rotwein P. 1996. Growth, differentiation, and survival: Multiple physiological functions for insulin-like growth factors. Physiol Rev 76:1005-1026.
51. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. 2002. Exercise training for claudication. N Engl J Med 347:1941-1951.
52. Stewart CE, Newcomb PV, Holly JM. 2004. Multifaceted roles of TNF-alpha in myoblast destruction: A multitude of signal transduction pathways. J Cell Physiol 198:237-247.
53. Tisdale MJ. 2009. Cancer Cachexia. Physiol Review 81:381-440.
54. Tollefsen SE, Sadow JL, Rotwein P. 1989. Coordinate expression of insulin-like growth factor II and its receptor during muscle differentiation. Proc Natl Acad Sci USA 86:1543-1547. (Pubitemid 19078939)
55. 12 myotubes through down-regulation of TNF-R2 and increased NF-kappaB activity. Cell Signal 17:1333-1342.
56. Yaffe D, Saxel O. 1977. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 270:725-727. (Pubitemid 8239246)